Lipoprotein(a) is supported by mechanistic, epidemiologic, and genetic evidence as a causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease.
Lipoprotein(a) (Lp(a)) is an established risk factor for multiple cardiovascular diseases. Several lines of evidence including mechanistic, epidemiologic, and genetic studies support the role of Lp(a) as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis/calcific aortic valve disease (AS/CAVD). Limited therapies currently exist for the management of risk associated with elevated Lp(a), but several targeted therapies are currently in various stages of clinical development. In this review, we detail evidence supporting Lp(a) as a causal risk factor for ASCVD and AS/CAVD, and discuss approaches to managing Lp(a)-associated risk.
Bhatia et al. (Thu,) conducted a review in Atherosclerotic cardiovascular disease and aortic stenosis/calcific aortic valve disease. Lipoprotein(a) targeted therapies was evaluated. Lipoprotein(a) is supported by mechanistic, epidemiologic, and genetic evidence as a causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: